Nom du produit:1-(3-bromo-4-ethylphenyl)ethanone
IUPAC Name:1-(3-bromo-4-ethylphenyl)ethan-1-one
- CAS：90841-42-2
- Formule moléculaire：C10H11BrO
- Pureté：95%+
- Numéro de catalogue：CM588910
- Poids moléculaire：227.1
Pour une utilisation en R&D uniquement..
Détails du produit
- N° CAS:90841-42-2
- Formule moléculaire:C10H11BrO
- Point de fusion:-
- Code SMILES:CCC1=C(C=C(C=C1)C(=O)C)Br
- Densité:
- Numéro de catalogue:CM588910
- Poids moléculaire:227.1
- Point d'ébullition:
- N° Mdl:
- Stockage:
Column Infos
- Alectinib
- Genentech, a member of the Roche Group, has announced that its ALK inhibitor Alecensa® (Alectinib) met its primary endpoint of disease-free survival (DFS) at a scheduled interim analysis of the phase 3 ALINA trial. Alecensa as adjuvant therapy resulted in statistically significant DFS and clinically meaningful improvement.
Worldwide, lung cancer is one of the most common cancers, with NSCLC accounting for 80% to 85% of all lung cancer cases. Despite adjuvant chemotherapy, about half of patients with early-stage lung cancer experience cancer recurrence after surgery. Recent therapeutic innovations, including immunotherapy, have improved the outlook for some patients with early-stage NSCLC; however, there are currently no ALK inhibitors approved for early-stage ALK-positive disease. Alecensa is the first ALK inhibitor proven in a Phase 3 trial to reduce the risk of disease recurrence or death in patients with early-stage ALK-positive NSCLC.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.
Recherche 
+86 21 5895 0110 
